The successful identification of numerous T cell epitopes derived from tumor-associated antigens has opened the doors to the development of subunit vaccines for the treatment and prevention of cancer. Vaccines prepared from synthetic peptides representing these T cell epitopes constitute an attractive approach for the induction of anti-tumor immune responses because they are easily manufactured, simple to characterize, relatively stable and most importantly, extremely cost effective as compared to other types of vaccines. However, because of MHC restriction, a major drawback of peptide epitope based vaccines is that they offer limited population coverage. Moreover, since one single tumor antigen will not target all patients with one type of malignancy, T cell epitopes from several antigens will be needed to produce vaccines for broad use in each disease setting. During the 1st funding period, we have focused on the identification of peptide epitopes for cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) from CEA, MAGE3 and HER2/neu, which are commonly found on epithelial cancers. These epitopes could be used for developing peptide-based therapeutic vaccines for breast cancer. However, the use of peptide mixtures, or cocktails in clinical studies is a complex endeavor that is not only costly, but also frowned upon by regulatory agencies. Each peptide has to be produced separately under good manufacturing practices (GMP) and has to undergo individual quality control testing, which is very costly. Responding to this problem, we have designed peptide-based vaccines, which we named """"""""Trojan Antigens"""""""" (TA) that allow the use of multiple T cell epitopes in a single construct. Using murine T cell epitopes we have shown that the TA can generate MHC:peptide complexes in a proteosome/TAP independent fashion and are capable of inducing strong immune responses in vaccinated mice. For the present grant, we would like to apply the technology of TA to human CTL and HTL epitopes and evaluate their immunogenicity in HLA transgenic mice. These results will serve as preclinical data for the initiation of clinical trials in cancer patients. The following specific aims are proposed: 1) To evaluate the immunogenicity of TA containing multiple CTL epitopes from CEA, MAGE3 and HER2/neu in HLA-A2 transgenic mice. 2) To evaluate the immunogenicity of TA containing CTL and HTL epitopes from CEA, MAGE3 and HER2/neu in HLA-A2/-DR4double transgenic mice. 3) To study anti-tumor immunity of TA containing multiple CTL and HTL epitopes in HLA-A2/-DR4 mice expressing the ratHER21neu oncogene. We believe that by completing the above specific aims, we will generate sufficient preclinical data to take this approach into the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA080782-09
Application #
7249460
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Muszynski, Karen
Project Start
1999-05-01
Project End
2009-05-28
Budget Start
2007-03-01
Budget End
2009-05-28
Support Year
9
Fiscal Year
2007
Total Cost
$312,971
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Lee, Sujin; Yagita, Hideo; Sayers, Thomas J et al. (2010) Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. Cancer Immunol Immunother 59:1073-81
Cho, Hyun-Il; Celis, Esteban (2009) Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69:9012-9
Kobayashi, Hiroya; Azumi, Makoto; Kimura, Yuka et al. (2009) Focal adhesion kinase as an immunotherapeutic target. Cancer Immunol Immunother 58:931-40
Assudani, Deepak; Cho, Hyun-Il; DeVito, Nicholas et al. (2008) In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 68:9892-9
Kobayashi, Hiroya; Celis, Esteban (2008) Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol 20:221-7
Kobayashi, Hiroya; Nagato, Toshihiro; Takahara, Miki et al. (2008) Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res 68:901-8
Cho, Hyun-Il; Niu, Guilian; Bradley, Norma et al. (2008) Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. Cancer Immunol Immunother 57:1695-703
Kennedy, Richard; Celis, Esteban (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222:129-44
Nava-Parada, Pilar; Forni, Guido; Knutson, Keith L et al. (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67:1326-34
Kobayashi, Hiroya; Nagato, Toshihiro; Sato, Keisuke et al. (2007) Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res 67:5498-504

Showing the most recent 10 out of 37 publications